PE20190421A1 - Metodo para prevenir o tratar la perdida de la audicion - Google Patents
Metodo para prevenir o tratar la perdida de la audicionInfo
- Publication number
- PE20190421A1 PE20190421A1 PE2019000369A PE2019000369A PE20190421A1 PE 20190421 A1 PE20190421 A1 PE 20190421A1 PE 2019000369 A PE2019000369 A PE 2019000369A PE 2019000369 A PE2019000369 A PE 2019000369A PE 20190421 A1 PE20190421 A1 PE 20190421A1
- Authority
- PE
- Peru
- Prior art keywords
- hearing loss
- prevent
- treat hearing
- pamapimod
- difluorophenoxy
- Prior art date
Links
- 206010011878 Deafness Diseases 0.000 title abstract 2
- 230000010370 hearing loss Effects 0.000 title abstract 2
- 231100000888 hearing loss Toxicity 0.000 title abstract 2
- 208000016354 hearing loss disease Diseases 0.000 title abstract 2
- HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 abstract 2
- -1 2,4-difluorophenoxy Chemical group 0.000 abstract 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 abstract 1
- 229940126033 PPAR agonist Drugs 0.000 abstract 1
- 239000000969 carrier Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000007850 degeneration Effects 0.000 abstract 1
- 239000003085 diluting agent Substances 0.000 abstract 1
- 210000002768 hair cell Anatomy 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 229940043355 kinase inhibitor Drugs 0.000 abstract 1
- 102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 abstract 1
- JYYLVUFNAHSSFE-UHFFFAOYSA-N pamapimod Chemical compound O=C1N(C)C2=NC(NC(CCO)CCO)=NC=C2C=C1OC1=CC=C(F)C=C1F JYYLVUFNAHSSFE-UHFFFAOYSA-N 0.000 abstract 1
- 229950001749 pamapimod Drugs 0.000 abstract 1
- 239000002307 peroxisome proliferator activated receptor agonist Substances 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 abstract 1
- 229960005095 pioglitazone Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0046—Ear
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cosmetics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Referido a un metodo para prevenir o tratar la perdida de la audicion e inhibir la degeneracion o muerte de celulas ciliadas que consiste en utilizar una combinacion farmaceutica que comprende: a) un agonista de PPAR tal como pioglitazona; b) un inhibidor de la quinasa p38 de formula I, donde un compuesto seleccionado es 6-(2,4-difluorofenoxi)-2-[3-hidroxi-1-(2-hidroxietil)-propilamino]-8-metil-8H-pirido[2,3-(i]pirimidin-7-ona (pamapimod); y opcionalmente c) uno o mas diluyentes, excipientes o portadores farmaceuticamente aceptables.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16184541 | 2016-08-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20190421A1 true PE20190421A1 (es) | 2019-03-19 |
Family
ID=56740115
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2019000369A PE20190421A1 (es) | 2016-08-17 | 2017-08-15 | Metodo para prevenir o tratar la perdida de la audicion |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20190209568A1 (es) |
| EP (1) | EP3500258A1 (es) |
| JP (1) | JP2019528273A (es) |
| KR (1) | KR20190039142A (es) |
| CN (1) | CN109562105A (es) |
| AU (1) | AU2017313296A1 (es) |
| BR (1) | BR112019003006A2 (es) |
| CA (1) | CA3033887A1 (es) |
| CL (1) | CL2019000410A1 (es) |
| CO (1) | CO2019001402A2 (es) |
| EA (1) | EA201990220A1 (es) |
| IL (1) | IL264625A (es) |
| MA (1) | MA45981A (es) |
| MX (1) | MX2019001819A (es) |
| PE (1) | PE20190421A1 (es) |
| PH (1) | PH12019550015A1 (es) |
| SG (1) | SG11201900776TA (es) |
| WO (1) | WO2018033543A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3820526B1 (en) * | 2018-07-13 | 2024-01-24 | Kinarus AG | Combinations of ppar agonists and p38 kinase inhibitors for preventing or treating fibrotic diseases |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR240698A1 (es) | 1985-01-19 | 1990-09-28 | Takeda Chemical Industries Ltd | Procedimiento para preparar compuestos de 5-(4-(2-(5-etil-2-piridil)-etoxi)benzil)-2,4-tiazolidindiona y sus sales |
| US5421818A (en) | 1993-10-18 | 1995-06-06 | Inner Ear Medical Delivery Systems, Inc. | Multi-functional inner ear treatment and diagnostic system |
| TWI249401B (en) * | 1999-04-14 | 2006-02-21 | Takeda Chemical Industries Ltd | Agent for improving ketosis |
| US20020151491A1 (en) * | 2000-11-28 | 2002-10-17 | Jian-Dong Li | Composition and method for treating the over-production of mucin in diseases such as otitis media using an inhibitor of MUC5AC |
| AU2002256615B2 (en) | 2001-02-12 | 2007-09-13 | F. Hoffmann-La Roche Ag | 6-substituted pyrido-pyrimidines |
| DE602004005238T2 (de) | 2003-11-13 | 2007-11-08 | F. Hoffmann-La Roche Ag | Hydroxyalkylsubstituierte pyrido-7-pyrimidin-7-one |
| CA2568028A1 (en) | 2004-05-24 | 2005-12-08 | Auris Medical, Llc. | Combined otic aspirator and medication dispenser |
| WO2008151992A2 (en) | 2007-06-15 | 2008-12-18 | F. Hoffmann-La Roche Ag | A novel process for the preparation of 3-amino-pentan-1,5-diol |
| BR112017016909A2 (pt) * | 2015-02-11 | 2018-03-27 | Support Venture Gmbh | método de prevenção ou tratamento de perda de audição |
| AU2017277478B2 (en) * | 2016-06-08 | 2023-03-16 | Support-Venture Gmbh | Pharmaceutical combinations for treating cancer |
-
2017
- 2017-08-15 CA CA3033887A patent/CA3033887A1/en not_active Abandoned
- 2017-08-15 CN CN201780049505.9A patent/CN109562105A/zh active Pending
- 2017-08-15 PE PE2019000369A patent/PE20190421A1/es unknown
- 2017-08-15 EP EP17757503.2A patent/EP3500258A1/en not_active Withdrawn
- 2017-08-15 WO PCT/EP2017/070683 patent/WO2018033543A1/en not_active Ceased
- 2017-08-15 JP JP2019508866A patent/JP2019528273A/ja not_active Withdrawn
- 2017-08-15 EA EA201990220A patent/EA201990220A1/ru unknown
- 2017-08-15 BR BR112019003006-9A patent/BR112019003006A2/pt not_active IP Right Cessation
- 2017-08-15 US US16/325,686 patent/US20190209568A1/en not_active Abandoned
- 2017-08-15 KR KR1020197004579A patent/KR20190039142A/ko not_active Ceased
- 2017-08-15 MX MX2019001819A patent/MX2019001819A/es unknown
- 2017-08-15 AU AU2017313296A patent/AU2017313296A1/en not_active Abandoned
- 2017-08-15 MA MA045981A patent/MA45981A/fr unknown
- 2017-08-15 SG SG11201900776TA patent/SG11201900776TA/en unknown
-
2019
- 2019-01-28 PH PH12019550015A patent/PH12019550015A1/en unknown
- 2019-02-03 IL IL264625A patent/IL264625A/en unknown
- 2019-02-14 CL CL2019000410A patent/CL2019000410A1/es unknown
- 2019-02-15 CO CONC2019/0001402A patent/CO2019001402A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3033887A1 (en) | 2018-02-22 |
| PH12019550015A1 (en) | 2019-07-24 |
| AU2017313296A1 (en) | 2019-02-14 |
| MA45981A (fr) | 2019-06-26 |
| CN109562105A (zh) | 2019-04-02 |
| CO2019001402A2 (es) | 2019-02-19 |
| JP2019528273A (ja) | 2019-10-10 |
| EA201990220A1 (ru) | 2019-08-30 |
| BR112019003006A2 (pt) | 2019-05-14 |
| SG11201900776TA (en) | 2019-03-28 |
| KR20190039142A (ko) | 2019-04-10 |
| WO2018033543A1 (en) | 2018-02-22 |
| IL264625A (en) | 2019-02-28 |
| CL2019000410A1 (es) | 2019-06-28 |
| US20190209568A1 (en) | 2019-07-11 |
| MX2019001819A (es) | 2019-06-13 |
| EP3500258A1 (en) | 2019-06-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1245677A1 (zh) | 用於治疗炎症和癌症的杂环itk抑制剂 | |
| MX395066B (es) | Método para tratar cáncer usando una combinación de agentes que dañan el adn e inhibidores de proteína relacionada con ataxia telangiectasia y rad3 (atr). | |
| NZ742208A (en) | Topical pharmaceutical formulations for treating inflammatory-related conditions | |
| EA201991556A1 (ru) | Ингибиторы фосфодиэстеразы и способы лечения микробной инфекции | |
| CL2018001145A1 (es) | Compuestos inhibidores de jak quinasa para el tratamiento de enfermedad respiratoria | |
| EA201991884A2 (ru) | Ингибиторы g12c kras | |
| MX2018007774A (es) | Compuestos heterociclicos como inmunomoduladores. | |
| PH12019501639A1 (en) | Jaki selective inhibitors | |
| MX2021000148A (es) | Inhibidores eterociclicos de erk1 y erk2 y su uso en el tratamiento del cancer. | |
| EA201991412A1 (ru) | Ингибиторы поли(адф-рибоза)полимеразы (parp) | |
| MX2018000577A (es) | Compuestos de pirazolo[1,5-a]piridina sustituidos como inhibidores de la ret quinasa. | |
| MX387097B (es) | Formulaciones oftalmicas de inhibidores de tirosina quinasa, metodos de uso de las mismas y metodos de preparacion de las mismas. | |
| BR112016024057A2 (pt) | inibidores de quinases heterocíclicos | |
| MX386542B (es) | Derivados de la 2,3-dihidro-isoindol-1-ona, como inhibidores de la btk quinasa y composiciones farmacéuticas que los incluyen. | |
| CO2017003838A2 (es) | Compuestos de aminopurina sustituida, composiciones del mismo, y métodos de tratamiento con los mismos | |
| MX2018002889A (es) | Compuesto de pirimidina fusionada o sal del mismo. | |
| DOP2021000077A (es) | Derivados de quinolina como inhibidores de la integrina alfa4beta7 | |
| AU2018347307A1 (en) | Heterocyclic compounds and uses thereof | |
| EA201790078A1 (ru) | Ингибиторы mnk и связанные с ними способы | |
| PH12019501261A1 (en) | Heterocyclic inhibitors of mct4 | |
| EA201692268A1 (ru) | Ингибиторы фосфатидилинозитол-3-киназы | |
| DK4053128T3 (da) | 5-(2-(2,5-difluorphenyl)pyrrolidin-1-yl)-3-(1h-pyrazol-1-yl)pyrazolo[1,5-a]pyrimidinderivater og relaterede forbindelser som trk-kinasehæmmere til cancerbehandling | |
| MX2021012418A (es) | Compuestos heterociclicos y sus usos. | |
| MX394860B (es) | Metodo para tratar cancer usando una combinacion de agentes que dañan adn e inhibidores de proteina cinasa dependiente de adn (adn-pk). | |
| EA201692557A1 (ru) | Хинолизиноновые производные в качестве ингибиторов pi3k |